Beneficial Effects of Ethyl Pyruvate through Inhibiting High-Mobility Group Box 1 Expression and TLR4/NF-κB Pathway after Traumatic Brain Injury in the Rat by Su, Xingfen et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2011, Article ID 807142, 10 pages
doi:10.1155/2011/807142
Research Article
BeneﬁcialEffectsof Ethyl Pyruvate through Inhibiting
High-Mobility GroupBox 1Expressionand TLR4/NF-κB Pathway
afterTraumatic Brain Injury inthe Rat
Xingfen Su,Handong Wang, JinbingZhao, HaoPan, andLei Mao
Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Jiangsu Province,
Nanjing 210002, China
Correspondence should be addressed to Handong Wang, hdwang nj@yahoo.com.cn
Received 17 January 2011; Accepted 21 March 2011
Academic Editor: Tˆ ania Silvia Fr¨ ode
Copyright © 2011 Xingfen Su et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethyl pyruvate (EP) has demonstrated neuroprotective eﬀects against acute brain injury throughits anti-inﬂammatory action. The
nuclear protein high-mobility group box 1 (HMGB1) can activate inﬂammatory pathways when released from dying cells. This
study was designed to investigate the protective eﬀects of EP against secondary brain injury in rats after Traumatic Brain Injury
(TBI). Adult male rats were randomly divided into three groups: (1) Sham + vehicle group, (2) TBI + vehicle group, and (3) TBI
+ EP group (n = 30 per group). Right parietal cortical contusion was made by using a weight-dropping TBI method. In TBI + EP
group, EP was administered intraperitoneally at a dosage of 75mg/kg at 5min, 1 and 6 h after TBI. Brain samples were harvested
at 24 h after TBI. We found that EP treatment markedly inhibited the expressions of HMGB1 and TLR4, NF-κB DNA binding
activity and inﬂammatory mediators, such as IL-1β,T N F - α and IL-6. Also, EP treatment signiﬁcantly ameliorated beam walking
performance,brainedema,andcorticalapoptoticcelldeath.TheseresultssuggestthattheprotectiveeﬀectsofEPmaybemediated
by the reduction of HMGB1/TLR4/NF-κB-mediated inﬂammatory response in the injured rat brain.
1.Introduction
Traumatic brain injury (TBI) usually leads to devastating
neurological deﬁcits and disabilities [1]. Yet, there is current
lacking of eﬀective treatment that can improve clinical
outcome. TBI has been classiﬁed into primary injury and
secondaryinjury[2].Theprimaryinjuryisunderstoodasthe
result of the mechanical forces acting on the injured brain.
The secondary injury is due to the complex biochemical and
pathophysiological changes that follow the primary insults
[3]. Of the many pathophysiological events that may con-
tribute to this delayed injury, posttraumatic inﬂammation
and apoptosis have been suggested to contribute to the
secondary brain injury and to result in a worsening of
neurologic outcome [4, 5].
High-mobility group box 1 (HMGB1) was originally
identiﬁed as a DNA-binding protein that functions as a
structural cofactor critical for proper transcriptional reg-
ulation in somatic cells [6]. HMGB1 can be actively and
passivelyreleasedfromthenecroticcellsotherthanapoptotic
cells, and then triggers inﬂammation [7, 8]. Recently, much
evidence identiﬁes HMGB1 as a cytokine-like mediator
[9, 10]. The extracellular HMGB1 binds to the receptor
for advanced glycation end products (RAGE) and other
receptors, including TLR2 and TLR4 [6, 11]. And then
these receptors activate a common signaling pathway that
culminates in the activation of nuclear factor-kappa B (NF-
κB) transcription factors. As one of the most important
downstream molecules in TLRs signaling pathway, NF-κB
is a transcriptional factor required for the gene expression
of many inﬂammatory mediators, such as interleukin-1β
(IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-
6( I L - 6 )[ 12]. Our previous unpublished data suggested that
HMGB1 was upregulated and relocated after TBI. HMGB1
may implicate an important role in promoting inﬂammation
after TBI.
Ethyl pyruvate (EP) is a stable and lipophilic ester
derived from the endogenous metabolite pyruvic acid [13].2 Mediators of Inﬂammation
ThepharmacologicaleﬀectsofEPincludedownregulationof
the secretion of proinﬂammatory cytokines, amelioration of
redox-mediated damage to cells and tissues, and inhibition
of apoptosis [14]. EP protects various inﬂammatory tissue
injuries, such as lethal sepsis and systemic inﬂammation
[15], hemorrhagic shock [16], and stroke [17].
S e v e r a lp r e v i o u ss t u d i e sh a v ed e m o n s t r a t e dt h a tt r e a t -
ment with a solution containing EP down-regulated activa-
tion of the proinﬂammatory transcription factor, NF-κB, as
well as the expression of several proinﬂammatory proteins,
suchasTNF-α,IL -6[16,18].Recently,theprotectiveeﬀectof
EP on spinal cord injury and brain trauma has been reported
[19, 20]. Nevertheless till now, it is still unknown whether EP
can inﬂuence HMGB1/TLR4/NF-κB pathway and the pro-
duction of inﬂammatory agents in the brain tissue after TBI.
And EP was the ﬁrst described pharmacological inhibitor
for HMGB1 secretion [13]. Thus, the aim of the current
study was to determine whether EP could attenuate the
TBI-induced activation of HMGB1/TLR4/NF-κB signaling
pathway in the pericontusion area.
2.MaterialsandMethods
2.1. Animal Preparation. Male Sprague-Dawley rats (250
to 300g) were purchased from Animal Center of Chinese
Academy of Sciences, Shanghai, China. The rats were raised
on a 12-hour dark-light cycle circumstance with free access
to food and water. The protocols including all surgical pro-
ceduresandanimalusageswereapprovedbytheAnimalCare
and Use Committee of Nanjing University and conformed to
the Guide for the Care and Use of Laboratory Animals by the
National Institutes of Health.
2.2. Experimental Protocols. A minor modiﬁcation of the
Feeney’s weight-drop model was used to induce rat model
of cortical contusion trauma [21, 22]. After intraperitoneal
anesthesia with pentobarbital sodium (50mg/kg, i.p.), rats
were ﬁxed in the stereotactic apparatus. The scalp was
cleaned with iodophor, and aseptic techniques were used
throughout surgery. The scalp was cut open, and a 5mm
diameter bone window (the center of the bone window
was 1.5mm posterior and 2.5mm lateral to the bregma)
was drilled on the right side of the parietal skull. The
dura was exposed and kept intact. Focal brain injury was
induced by dropping a 40g steel rod with a ﬂat end from
a height of 25cm onto a piston (diameter 4mm) resting
on the dura. The piston was allowed to compress brain
tissue for a maximum depth of 5mm. Then the scalp was
sutured.Sham-operatedratswereanesthetized andmounted
in the stereotactic apparatus, with right parietal craniotomy
surgically prepared alone and without suﬀering the cortical
contusion. During recovery from anesthesia, the rats were
placed on a warm heating pad and covered with a warm
towel. And then the rats were returned to their cages and the
room temperature kept at 23 ± 1◦C.
Rats were randomly allocated into the following groups:
(a) TBI + EP group: the rats were subjected to TBI and
administered EP solution (dissolved in 0.9% saline solution,
10mg/mL) at a dosage of 75mg/kg via intraperitoneal
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Figure 1:Schematicrepresentationofthecontusioncortexinduced
by weight-dropping trauma and the detected area surrounding the
injured brain cortex.
injection (i.p.) 5min, 1 hour, and 6 hours after TBI (n = 30
total); (b) TBI group: the rats were subjected to TBI plus
administration (i.p.) equal volumes of 0.9% saline solution
(7.5mL/kg) without EP, 5min, 1 hour, and 6 hours after
TBI (n = 30 total); (c) Sham group: rats were subjected to
the surgical procedures as the above groups except for the
focal brain injury and to these rats were administered equal
volumes of 0.9% saline solution (7.5mL/kg) without EP
(administered i.p., 5min, 1 hour, and 6 hours after surgical
procedure) (n = 30 total). The dose and time-point were
chosen with minor change according to previous studies
[19, 23].
At 24 hours after surgery, beam-walking task was con-
ducted to test the function deﬁcits of the rats. And then
the rats were killed by an over dose of anesthesia agent.
The surrounding brain tissue of the injured cortex (Figure 1)
was dissected from the region that was less than 3mm
from the margin of the contusion site on ice and stored
in liquid nitrogen immediately until use. Six rats in each
group were sacriﬁced for Western bolt and enzyme-linked
immunosorbent assay (ELISA), six for RT-PCR, six for elec-
trophoretic mobility shift assay (EMSA),six for brainedema,
and the others were for immunohistochemistry study. For
immunohistochemistry study, the rats were transcardially
perfused with 0.1mol/L phosphate buﬀered saline (PBS,
4◦C )a n df o l l o w e db y4 %b u ﬀered formaldehyde; the brain
was immersed in 4% buﬀered formaldehyde overnight and
then embedded in paraﬃn.
2.3. Beam Walking Balance Task. Beam walking balance task
was used to assess locomotor function of rats after TBI as
previous described [24]. The rats underwent pretraining on
the wooden beam for 3 days prior to randomization. All
rats had a normal score (7) before surgery. The assessment
was performed at 24 hours after surgery before sacriﬁce.
In training and testing, rats were places on one end of the
120cm long, 2.5cm wide, elevated (50cm) wooden beam
and forced to enter a dark goal box (25cm wide, 25cmMediators of Inﬂammation 3
long, and 25cm high). A 60W light source was positioned
close to the starting point of the beam and provided the
only illumination in the room during test sessions, and white
noise (60dB) was used to encourage locomotion. The noise
was terminated after the animal traversed the beam into a
dark goal box. The time to transverse the beam and enter
the dark box was also recorded, and a trial was ended if the
animal had not entered the goal within 90s. Beam-walking
performance was rated using a 7-point rating scale, similar
to those previously published articles [24, 25]: (1) the rat
is unable to place the aﬀected hind limb on the horizontal
surface of the beam; (2) it places the aﬀected hind limb on
thehorizontalsurfaceofthebeamandmaintainsbalancebut
is unable to traverse the beam; (3) the rat traverses the beam
dragging the aﬀected hind limb; (4) it traverses the beam and
once places the aﬀected hind limb on the horizontal surface
of the beam; (5) the rat crosses the beam and places the
aﬀected hind limb on the horizontal surface of the beam to
aid less than half its steps; (6) the rat uses the aﬀected hind
limb to aid more than half its steps, and (7) the rat traverses
the beam with no more than 2 foot slips. The beam-walking
test was performed by an independent observer, who had
no prior knowledge of the experimental protocol and was
unaware of the grouping.
2.4.BrainWaterContent. Brainedemawasdeterminedusing
the wet-dry method as previously described [26]. Brieﬂy,
brain tissues around the contusion cortex were rapidly
harvested and immediately weighed to gain the wet weight.
The samples were dried in oven at 110◦C for 24 hours, and
then weighed again to get the dry weight. The brain water
edema was calculated by the formula: percentage of brain
water = [(wet weight − dry weight)/wet weight] × 100%.
2.5. RT-PCR Analysis. The levels of HMGB1 and TLR4
mRNA expression were determined by RT-PCR. Total RNA
was extracted with TRIzol reagent (Invitrogen Corpora-
tion, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Total cDNA was synthesized from the isolated
total RNA using a reverse transcriptional system. Brieﬂy,
5μg of total RNA was reverse transcribed using 0.5μg
oligo(dT)15U avian myeloblastosis virus reverse transcrip-
tase (Biouniquer Technology CO, LTD). The cDNA was
then ampliﬁed by PCR. The forward and reverse primers
were as follows: 5 -ATGGGCAAAGGAGATCCTA-3  and
5 -ATTCATCATCATCATCTTCT-3  for HMGB1 (646bp),
5 -TTGCCTTCATTACAGGGACTT-3  and 5 -CAGAGC-
GGCTACTCAGAAACT-3  for TLR4 (179bp), and 5 -
GCCATGTACGTAGCCATCCA-3  and 5 -GAACCGCTC-
ATTGCCGATAG-3  for β-actin (375bp) [27, 28]. PCR
ampliﬁcation was performed for 35 cycles of 30 seconds
at 94◦C, 50 seconds at 55◦C, and 50 seconds at 72◦C,
followed by a ﬁnal step of 7 minutes at 72◦C. PCR
products were detected by agarose gel electrophoresis in
2% NuSieve agarose gels (FMC, USA) and visualized by
ethidium bromide staining. The intensity of the bands was
quantiﬁed using ImageJ software, and the ratios of each gene
product normalized to β-actin product were considered as
the expression of each gene.
2.6. Western Blot Analysis. For western blot analysis, proper
size of tissues were completely homogenized and centrifuged
at 14000 ×gf o r1 5m i n u t e sa t4 ◦C. The supernatant was
collected. An equal volume of 6× SDS sample buﬀer was
added, and the samples were then boiled for 5 minutes.
Samples (50μg per lane) were subjected to electrophoresis
on 10% SDS-polyacrylamide gels for 45 minutes at 80V
followed by 100 minutes at 100V and then transferred
onto nitrocellulose for 1 hour at 100V. The membrane was
blocked with 5% skimmed milk for 2 hours at room tem-
perature, then incubated for 1 hour in the presence of anti-
HMGB1 monoclonal antibody (diluted 1:800, epitomics,
Inc., Burlingame, CA, USA), anti-TLR4 polyclonal antibody
(diluted 1:200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and β-actin (1:1000 dilution, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) was used as an internal control.
After the membrane was washed for 10 minutes each for
six times in PBS+Tween 20 (PBST), it was incubated in the
appropriate HRP-conjugated secondary antibody (diluted
1:400 in PBST) for 2 hours. The blotted protein bands were
visualized by enhanced chemiluminescence (ECL) Western
blot detection reagents (Amersham, Arlington Heights, IL,
USA) and were exposed to X-ray ﬁlm. Developed ﬁlms were
digitized using an Epson Perfection 2480 scanner (Seiko
Corp, Nagano, Japan). Optical densities were obtained using
Glyko Bandscan software (Glyko, Novato, CA, USA).
2.7. Nuclear Protein Extract and EMSA. Nuclear protein of
the brain tissue was extracted and quantiﬁed as previously
described [29]. Protein concentration was determined using
a bicinchoninic acid assay kit with boving serum albumin
as the standard (Pierce Biochemicals, Rockford, Ill, USA).
EMSAwasperformedusingacommercialkit(GelShiftAssay
System; Promega, Madison, WI) as previously described
[30]. Consensus oligonucleotide probe (5 -AGT TGA GGG
GAC TTT CCCAGG C-3 ) was end-labeled with [γ-32P]-
ATP (Free Biotech., Beijing, China) with T4-polynucleotide
kinase. Nuclear protein (20μg) was preincubated in a total
volume of 20μL in a binding buﬀer, consisting of 10mmol/L
Tris-HCl (PH 7.5), 1mmol/L MgCl2, 0.5mmol/L NaCl, 4%
glycerol, 0.5mmol/L EDTA, 0.5mmol/L DTT, and 2μgp o l y
dI-dC for 20 minutes at room temperature. After addition
of the 1μL 32P-labled oligonucleotide probe, the incubation
was continued for 20 minutes at room temperature. After
adding 1μL of gel loading buﬀer, the reaction was stopped
and the mixture was resolved by electrophoresis on 4%
nondenaturing polyacrylamide gel in 0.5× TBE buﬀer (Tris-
borate-EDTA) at 390V for 1 hour at 4◦C. The gel was
dried and exposed to X-ray ﬁlm (Fuji Hyperﬁlm, Tokyo,
Japan) at −70◦C with an intensifying screed. Levels of NF-κB
DNA binding activity were quantiﬁed by computer-assisted
densitometric analysis.
2.8. Enzyme-Linked Immunosorbent Assay (ELISA). The cor-
textissuewashomogenizedwithaglasshomogenizerin1mL
of buﬀer containing 1mM phenylmethylsulfonyl ﬂuoride,
1mg/L pepstatin A, 1mg/L aprotinin, and 1mg/L leupeptin
in phosphate-buﬀered saline solution (pH 7.2), and then
centrifuged at 12,000×gf o r2 0m i na t4 ◦C. The supernatant4 Mediators of Inﬂammation
was then collected, and total protein was determined by
using a bicinchoninic acid assay kit (Pierce Biochemicals,
Rockford, IL, USA). The levels of inﬂammatory cytokines
of the brain tissue were quantiﬁed using ELISA kits speciﬁc
for rat according to the manufacturers’ instructions (TNF-α,
from Diaclone Research, France; IL-1β,I L - 6f r o mB i o s o u r c e
Europe SA, Belgium) and previous study of our laboratory
[31].Thecytokinecontentsinthebraintissuewereexpressed
as pg per milligram protein.
2.9. Immunohistochemical Examinations and Cell Counting.
Immunohistochemistry was performed to ascertain the
immunoreactivity of HMGB1 and TLR4. Brieﬂy, the tissue
sections (4μm) were deparaﬃnized and rehydrated in gradi-
ent alcohol. And then the sections were incubated with anti-
HMGB1 monoclonal antibody (diluted 1:500, epitomics,
Inc., Burlingame, CA, USA) and anti-TLR4 polyclonal
antibody (diluted 1:100, Santa Cruz Biotechnology, Santa
Cruz,CA,USA)overnightat4◦C,followedbya15-minwash
in phosphate-buﬀered saline. After that the sections were
incubated with horseradish peroxidase (HRP-) conjugated
IgG (diluted 1:500, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) for 60 minutes at room temperature. 3,
3 -Diaminobenzidine–H2O2 solution was used to visualize
HMGB1 and TLR4. Those cells that HMGB1 translocated
from nucleus to cytoplasm were considered as HMGB1-
positive cells. The positive cells were identiﬁed, counted,
and analyzed in the section through the injured cortex by
a pathologist blinded to the experimental group. Five ﬁelds
within 0.5mm to the contusion cortex in each section,
three sections of each rat brain sample, and ﬁve rats in
each group were randomly selected and observed under
a light microscope (at ×400 magniﬁcation) (Eclipse E100,
Nikon, Japan). Then, the average percentage of HMGB1 and
TLR4 positive cells in each section were calculated as the
immunoreactivity of HMGB1 and TLR4 in the rat brains.
2.10. TUNEL Staining and Quantitation of Apoptotic Cells.
The formalin-ﬁxed tissues were embedded in paraﬃna n d
sectioned at 4μm thickness with a microtome. The sections
were detected for apoptotic cells by terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) method. An in situ cell death detection Kit
POD (ISCDD, Boehringer, Mannheim, Germany) was used
according to the manufacture’s protocol of the kit and our
previous study [29]. Microscopic examination of the stained
tissue sections was performed by a pathologist blinded to
the experimental group. TUNEL-positive cells were counted
in the section through the injured cortex. The extent of
brain damage was evaluated by apoptotic index, which was
the average percentage of TUNEL-positive cells in each
section counted in 10 cortical microscopic ﬁelds (at ×400
magniﬁcation).
2.11. Statistical Analysis. Densitometric quantiﬁcation and
analysis of the PCR, EMSA, and Western blot bands were
done with ImageJ software. SPSS 16.0 was used for the
statistical analysis (SPSS, Inc., Chicago, IL, USA). All data are
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Figure 2: Eﬀects of EP administration on functional outcomes in
contusion injured rats as evaluated by beam walking balance tasks.
Compared to rats in TBI group, EP administration attenuated the
injury induced impairment in beam walking balance performance
tested at 24 hours after TBI. Bars represent as mean ± SEM; n = 15,
eachgroup; ∗∗P<. 01versusShamgroup, #P<. 05versusTBIgroup.
expressed as mean ± SEM. The data were subjected to one-
way ANOVA followed by Tukey’s post-hoc test. Statistical
signiﬁcance was accepted with P<. 05.
3. Results
3.1. Ethyl Pyruvate Improved Beam Walking Balance Perfor-
mance of Rats after TBI. All rats had scores of 7 prior to
surgical procedure. As shown in Figure 2, the rats in Sham
group still had scores of 7 at 24 hours after sham-operation.
Compared with Sham group, motor function impairment
caused by TBI was signiﬁcant in the TBI group (P<. 01).
However, EP treatment signiﬁcantly improved the beam
walking balance performance of the rats 24 hours after TBI
(P<. 05) (Figure 2). (n = 15, each group; ∗∗P<. 01
compared with Sham group, #P<. 05 compared with TBI
group).
3.2. EP Ameliorated Cerebral Edema after TBI. Brain water
contentaveragedabout78.9%intheShamgroup.Compared
to Sham group, signiﬁcant increase of brain water content
was detected in the brain tissue surrounding the injured
cortex24 hours afterTBI(P<. 01). However, the brain water
content of injured brain was decreased by EP administration
as compared with TBI group (P<. 01) (Figure 3). These
results suggested that treatment with ethyl pyruvate could
attenuateratbrainedemafollowingTBI.(n = 6,eachgroup;
∗∗P<. 01 compared with Sham group, #P<. 05 compared
with TBI group).
3.3. Inﬂuence of EP on the mRNA Expression of HMGB1
and TLR4 in the Brain following TBI. HMGB1 and TLR4
mRNAs were expressed at low levels in the rat brain of ShamMediators of Inﬂammation 5
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Figure 3: Alteration in brain water content in Sham group, TBI
group, and TBI + EP group. The brain water content was increased
signiﬁcantly at 24 hours after TBI. EP administration markedly
decreasedbrainwatercontent24hafterTBI.Barsrepresentasmean
± SEM; n = 6, each group; ∗∗P<. 01 versus Sham group, #P<. 05
versus TBI group.
group. The mRNA expression of HMGB1 and TLR4 in the
cortex surrounding to the contusion core were signiﬁcantly
increased after TBI compared with that of the Sham group
(P<. 01). But in the EP group, the levels of HMGB1
and TLR4 mRNA in the injured cortex were signiﬁcantly
decreasedcomparedwiththeTBIgroup(P<. 01)(Figure 4).
(n = 6, each group; ∗P<. 05, ∗∗P<. 01 compared with Sham
group, #P<. 05, ##P<. 01 compared with TBI group).
3.4. Eﬀe c to fE Po nH M G B 1a n dT L R 4P r o t e i nE x p r e s s i o n
in the Injured Brain. To determine the inﬂuence of EP
on HMGB1 and TLR4 expression on injured brain after
TBI, Western blot was performed to detect the changes of
HMGB1 and TLR4 protein as described in Materials and
Methods.ThewesternblotshowedlowlevelsofHMGB1and
TLR4 protein in the Sham group (Figure 5). But the protein
levels of HMGB1 and TLR4 were signiﬁcantly increased in
the tissue surrounding injured cortex 24h following TBI
compared with Sham group (P<. 01) (Figure 5). After EP
administration, the increased levels of HMGB1 and TLR4
were remarkably suppressed in the TBI + EP group (P<. 01)
(Figure 5). (n = 6, each group; ∗P<. 05, ∗∗P<. 01 compared
with Sham group, #P<. 05, ##P<. 01 compared with TBI
group).
3.5.EPAdministrationInhibitedNF-κBDNABindingActivity
after TBI. NF-κB DNA binding activity of the injured brain
tissue was assessed by EMSA autoradiography. As shown
in Figure 6 upper panel, low NF-κB binding activity (weak
EMSA autoradiography) was found in the Sham group. But
compared with the Sham group, NF-κB binding activity was
signiﬁcantly increased in the TBI group (P<. 01). After
administering three doses of EP to rats suﬀered TBI, the
NF-κB binding activity was signiﬁcantly downregulated in
the brain tissue surrounding the injured cortex (P<. 01)
(Figure 6 lower panel). (n = 6, each group; ∗∗P<. 01
compared with Sham group, ##P<. 01 compared with TBI
group).
3.6. Ethyl Pyruvate Administration Attenuated Production of
proinﬂammatory Cytokines in the Injured Brain after TBI. As
shown in Figure 7, concentrations of IL-1β,T N F - α and IL-6
w e r ei nl o wl e v e l si nt h er a tb r a i n so fS h a mg r o u p .B u ta f t e r
suﬀering TBI, the levels of these three cytokines were greatly
increased.AndEPtreatmenttotheratsafterTBIsigniﬁcantly
decreased the production of the IL-1β,T N F - α, and IL-6 in
the injured brains. (n = 6, each group; ∗P<. 05, ∗∗P<. 01
compared with Sham group, #P<. 05, ##P<. 01 compared
with TBI group).
3.7. Treatment with EP to the Rats after TBI Repressed
Percentage of HMGB1 and TLR4 Positive Cells in the Injured
Brain. Immunohistochemistry was performed to investigate
the localization and expression of HMGB1 and TLR4 in
the rat brain. Those brain cells that HMGB1 translocated
from nucleus to cytoplasm were considered as HMGB1-
positive cells. Few HMGB1 and TLR4-positicve cells were
observed in the Sham group. Increased HMGB1 and TLR4-
positive cells were present in the TBI group (Figure 8(a)).
However, EP treatment to the rats signiﬁcantly decreased
HMGB1 and TLR4 expression. Arrows indicated HMGB1
and TLR4-positive cells in the surrounding region of injured
cortex after TBI (Figure 8(a)). Semiquantitative analysis for
immunohistochemistry showed the same results as Western
blot analysis. In TBI group, the percentage of HMGB1 and
TLR4 positive cells were signiﬁcantly increased as compared
with that in the Sham group (P<. 01). In TBI + EP group,
when compared with TBI group, the percentage of HMGB1
andTLR4positivecellsweresigniﬁcantlydecreased(P<. 01)
(Figure 8(b)). These results demonstrated that EP could sig-
niﬁcantly reduce the HMGB1 and TLR4 immunoreactivity
in the injured brain after TBI. (n = 6, each group; ∗∗P<. 01
compared with Sham group, ##P<. 01 compared with TBI
group).
3.8. EP Administration Suppressed Cortical Apoptosis in the
Injured Brain. Few TUNEL-positive apoptotic cells were
foundintheratbrainsofShamoperatedgroup(Figure 9(a)).
In the TBI group, the apoptotic index in the cortex
surrounding the injured cortex was signiﬁcantly increased
compared with the Sham group (P<. 01) (Figures 9(b)
and 9(d)). In the TBI + EP group, when compared with
that in the TBI group, the apoptotic index in the studied
cortexwassigniﬁcantlydecreased(P<. 05)(Figures9(c)and
9(d)). This result showed that EP treatment after TBI could
suppress cell death in the cortex surrounding the injured
cortex (Figure 9). (n = 6, each group; ∗∗P<. 01 compared
with Sham group, #P<. 05 compared with TBI group).6 Mediators of Inﬂammation
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Figure 4: HMGB1 and TLR4 mRNA expression in the rat brain of the Sham group, TBI group, and TBI + EP group. Upper panel:
representative RT-PCR bands show the HMGB1 and TLR4 mRNA expression in each group. Bottom panel: density of mRNA bands from
each group. Quantitative analysis of the RT-PCR results for the expression of HMGB1 and TLR4 mRNA. It shows that TBI induced a
marked increase of HMGB1 and TLR4 mRNA expression in the brain tissue surrounding the contusion cortex compared with the Sham
group (P<. 01). After treatment with EP, the HMGB1 and TLR4 mRNA expressions were signiﬁcantly downregulated compared to the TBI
group (P<. 05). Bars represent as mean ± SEM; n = 6, each group; ∗∗P<. 01, ∗P<. 05 versus Sham group, #P<. 05 versus TBI group.
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Figure 5: Expression of HMGB1 and TLR4 protein in the rat brain of the Sham group, TBI group, and TBI + EP group. Upper panel
represents autoradiogram of the HMGB1 and TLR4 protein expression by Western blot. Bottom panel is quantitative analysis of the Western
blot results for the expression of HMGB1 and TLR4 protein. TBI induced a marked increase of HMGB1 and TLR4 protein expression in
the brain tissue surrounding the contusion cortex compared to the Sham group (P<. 01). The HMGB1 and TLR4 protein expressions were
signiﬁcantly downregulated compared to the TBI group after EP treatment (P<. 05). Bars represent as mean ± SEM; n = 6, each group;
∗∗P<. 01 versus Sham group, #P<. 05 versus TBI group.Mediators of Inﬂammation 7
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Figure 6: NF-κB DNA binding activity in the brain tissue surroun-
ding the contusion cortex in Sham group, TBI group, and TBI
+ EP group. Upper panel: EMSA autoradiography of NF-κB
DNA binding activity. Lower panel: quantiﬁcation of NF-κBD N A
binding activity was performed by densitometric analysis. As
compared with Sham group, NF-κB binding activity measured by
EMSA was signiﬁcantly increased after TBI. However, compared to
TBI group, EP treatment signiﬁcantly suppressed NF-κB binding
activationinTBI+EPgroup.Barsrepresentasmean ±SEM;n = 6,
each group; ∗∗P<. 01 versus Sham group, P<. 01 versus TBI group.
4. Discussion
There is a wealth of evidence to suggest that inﬂamma-
tion plays an important role in the pathophysiology of
TBI. TBI initiates the inﬂammatory response by disrupting
the blood-brain barrier, creating edema, and inﬁltration
of inﬂammatory cells [32]. There is lacking of eﬀective
treatmentinclinical.Therefore,itisacriticalneedtodevelop
new pharmacologic therapies for TBI treatment through
inhibiting inﬂammatory responses.
Ethyl pyruvate has been shown to exert cytoprotective
actions and anti-inﬂammatory eﬀects by inhibiting the
expression of various proinﬂammatory mediates as well as
HMGB1 in several in vitro and in vivo models [14, 15].
Recently, EP has been reported to provide a neuroprotective
eﬀect on cerebral ischemia [17], spinal cord injury [19], and
traumatic brain injury [20].
Inthepresentstudy,wedemonstratedthatethylpyruvate
exerts beneﬁcial eﬀects in a rat weight-dropping model
of TBI. The results showed that TBI resulted in brain
edema, apoptotic cell death, and motor functional deﬁcits.
Meanwhile, traumatic brain injury induced inﬂammatory
responses in the brain tissue, characterized by enhancing
NF-κB activation, induced expression of proinﬂammatory
mediates, such as IL-1β,T N F - α, and IL-6. Also, the expres-
sions of HMGB1 and TLR4 were upregulated remarkably
0
20
40
60
80
100
C
y
t
o
k
i
n
e
s
c
o
n
t
e
n
t
(
p
g
/
m
g
)
IL-1β TNF-α IL-6
Sham
TBI
T B I+E P
∗∗
∗∗
∗∗
##
##
#
Figure 7: Changes of inﬂammatory mediators in the injured brain
of rats determined by ELISA in Sham group, TBI group, and TBI
+ EP group. The ﬁgure indicated that the levels of TNF-α,I L - 1 β,
andIL-6intheinjuredbraintissueweresigniﬁcantlyincreasedafter
TBI. In the TBI + EP group, the concentrations of TNF-α,I L - 1 β,
and IL-6 were markedly downregulated when treated with EP. Bars
represent as mean ± SEM; n = 6, each group; ∗∗P<. 01 compared
with Sham group, #P<. 05, ##P<. 01 compared with TBI group.
after TBI. Moreover, our results indicated that EP admin-
istration reduced (1) brain edema, (2) the mRNA and
protein expressions of HMGB1 and TLR4, (3) NF-κBD N A
binding activity, (4) proinﬂammatory cytokines expression,
(5) inhibited HMGB1 translocation, (6) suppressed apop-
totic cell death, and (7) improved beam walking balance
performance in the rats suﬀered TBI. All of these support the
viewthatEPreducessomedegreeofsecondaryinﬂammation
and improves motor function recovery after TBI. To our
knowledge, these ﬁndings demonstrated for the ﬁrst time
that EP may attenuate the TBI-induced HMGB1/TLR4/ NF-
κB signaling pathway activation which may exert on the
development of secondary brain damage in rat after TBI.
HMGB1 is a nonhistone nuclear protein with dual
function. Inside the cells, HMGB1 binds to DNA and plays a
role in transcriptional regulation. Outside the cells, HMGB1
serves as a cytokine-like mediator of inﬂammation [6].
HMGB1 can be actively or passively released from necrotic
or dying cells [7]. Both mechanisms can produce the release
ofsigniﬁcantamountsofextracellularHMGB1.HMGB1can
bind to cell surface and signal through receptors including
RAGE(receptorforadvancedglycationendproducts),TLR2,
and TLR4 after being released into the extracellular milieu
[6, 11]. Then, these receptors lead to activation of NF-κB
signaling and ﬁnally promote many cytokines production,
such as TNF-α,I L - 6 ,a n dI N F - γ [6, 33]. In fact, previous
studies in our lab demonstrated that TLR2 and TLR48 Mediators of Inﬂammation
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Figure 8: Immunohistochemistry staining showed the expression
of HMGB1 and TLR4 protein in the brain tissue. The cytoplasm
or extranuclear HMGB1 staining cells were considered as HMGB1-
positive cells. (a) Immunohistochemistry staining showed that
HMGB1 distributed mostly in the cell nucleus within the Sham
group. Few HMGB1 and TLR4 positive cells were observed in the
representative cortex. However, in the TBI group, TBI induced
HMGB1 redistribution and TLR4 expression. HMGB1 cytoplasm
translocation was observed in brain cells. However, EP treatment
to the rats signiﬁcantly decreased HMGB1 translocation and TLR4
expression. Arrows indicated representatively HMGB1 and TLR4
positive cells in the surrounding region of contusion cortex. Scale
bars: 50μm. (b) Quantiﬁcation of HMGB1 and TLR4 positive cells
in each group. TBI induced a marked increase of HMGB1 and
TLR4 positive cells in the brain tissue surrounding the contusion
cortex compared to the Sham group (P<. 01). And EP treatment
signiﬁcantly reduced HMGB1 and TLR4 positive cells in TBI +
EP group than that compared to the TBI group (P<. 01). Bars
representasmean ±SEM;n = 6,eachgroup; ∗∗P<. 01versusSham
group, ##P<. 01 versus TBI group.
receptors and NF-κB signaling pathway play a critical role
in the inﬂammatory response to TBI [22, 27, 34]. But
the principal TLRs ligands in the brain after TBI remain
unknown. Our present study showed that the expression
of HMGB1 mRNA and protein were signiﬁcantly increased
(Figures 4(a) and 5(a)) and translocated from nucleus to
cytoplasm 24h after TBI (Figure 8(a)). These results indicate
that HMGB1 was involved in the proinﬂammatory stress
responsetoTBI.HMGB1mayactasoneoftheTLR4ligands,
signaling through the TLR4/NF-κB pathway which regulated
the proinﬂammatory cytokines production after TBI.
HMGB1hasbeenconsideredasoneoftheDamageAsso-
ciate Molecular Patterns (DAMPs) participating in many
sterile inﬂammation diseases, such ischemia reperfusion
injury and close trauma [8, 35]. Moreover, HMGB1 was
reported upregulated after experimental spinal cord injury
and associated with neuronal cell apoptosis [36]. Similar
results were obtained from the present study. Treatment with
either Anti-HMGB1 antibody or other HMGB1 inhibitors
such as EP is beneﬁcial in many preclinical inﬂammatory
disease models [37, 38]. EP was the ﬁrst described phar-
macological inhibitor of HMGB1 secretion. Furthermore,
in this study, we showed that EP treatment signiﬁcantly
inhibited HMGB1 expression and cytoplasm translocation
(Figures 4(a), 5(a),a n d8). Meanwhile, as the same results
as previous studies [22, 27], we showed that TLR4, NF-
κB binding activation, and proinﬂammatory mediates, such
as IL-1β,T N F - α, and IL-6 were signiﬁcantly upregulated
after TBI (Figures 4–8). EP treatment to the injured rats
could profoundly inhibit the expression of TLR4 and NF-
κB DNA binding activation, as well as the expression of
several proinﬂammatory proteins, such as IL-1β,T N F - α,I L -
6, and inﬂammatory mediates. Recently, Moro and Sutton
[20] reported that EP or pyruvate treatments signiﬁcantly
improvedrecoveryofbeamwalking,neurologicalscores,and
hippocampus neuronal loss after cortical contusion injury.
They further indicated that the signiﬁcant neuroprotection
of EP was accompanied by the suppression of microglia
activation and proinﬂammatory cytokines and improved
metabolism. Our results further indicated that EP admin-
istration following TBI could reduce apoptotic cell death
in the injured cortex (Figure 9)a n db r a i ne d e m a( Figure 3)
and improve motor function recovery (Figure 2). Together,
these results indicate that inhibition of HMGB1/TLR4/NF-
κB pathway activation by EP resulted in less apoptosis and
better functional recovery.
Our study has some limitations. First, we began to treat
EP at 5min after TBI. It is unlikely that EP treatment
could begin at this time point in clinical practice, which
may limit the clinical use of EP. However, previous research
shows that EP suppresses cerebral ischemic injury with a
wide therapeutic window as late as 24 hours after stroke
[17]. In our further study, we will explore more practical
and eﬀective therapeutic window of EP in rat TBI model.
Second, we used single EP concentration at 75mg/kg in
this study. In a future study, multiple EP concentrations
should be evaluated to conﬁrm the most appropriate EP
concentration for maximal neuroprotection in rats after TBI.
Third,previousstudyshowedthatsodiumpyruvate(SP)and
EP both have neuroprotective eﬀects in rat model of cortical
contusion injury [20]. But, we did not study the protective
eﬀects of SP in our present study. We will further conﬁrm
whether SP has the same protective mechanisms as EP and
the beneﬁcial eﬀects of SP by comparing with EP in TBI
model.
In summary, our data demonstrated the eﬀects of EP
on the HMGB1/TLR4/NF-κB pathway in the injured brainMediators of Inﬂammation 9
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Figure 9: TUNEL immunohistochemistry staining of the injured cortex in Sham group, TBI group, and TBI + EP group. (a) Sham group
rats showed few TUNEL apoptotic cells; (b) TBI group rats showed more TUNEL apoptotic cells stained as brown; (c) TBI + EP group rats
showed less TUNEL apoptotic cells than TBI group (scale bars, 50μm). (d) EP administration signiﬁcantly decreased the apoptotic index in
rat injured brain following TBI. Bars represent as mean ± SEM; n = 6, each group; ∗∗P<. 01 versus Sham group, #P<. 05 versus TBI group.
after TBI. We found that TBI could induce the expressions
of HMGB1 and TLR4, downstream factors (IL-1β,T N F -
α and IL-6), and increased NF-κB DNA binding activity
in the injured brain, which could be remarkably inhibited
by EP treatment. These results suggest that TBI induces
activation of HMGB1/TLR4/NF-κB signaling pathway in the
injured rat brain which might play a central role in the
inﬂammatory response that may lead to secondary damage
afterTBI.InhibitionofHMGB1secretionorreleaseindicates
a novel and promising strategy for the treatment of TBI. The
neuroprotective eﬀects of EP treatment in weight-dropping
TBI rat model may be associated with the inhibition of
HMGB1/TLR4/NF-κB pathway activation. Further study on
the eﬀects of EP in TBI might provide a novel therapeutic
agent for TBI treatment.
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